Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Altimmune, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

PEMVIDUTIDE 2.4 MG DELIVERED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL REDUCTION IN HEAVY DRINKING DAYS, THE PRIMARY ENDPOINT OF THE TRIAL IMPORTANT SECONDARY ENDPOINTS WERE ALSO MET, INCLUDING TWO-LEVEL REDUCTION IN WHO RISK DRINKING LEVELS AND ZERO HEAVY DRINKING DAYS, BOTH OF WHICH ARE RECOGNIZED BY THE FDA AS REGISTRATIONAL ENDPOINTS A GENERALLY FAVORABLE TOLERABILITY PROFILE WAS OBSERVED IN THE TRIAL CONFERENCE CALL TO BE HELD TODAY AT 8:00 AM ET GAITHERSBURG, MD., JULY 28, 2026 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON SERIOUS LIVER DISEASES, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE RECLAIM PHASE 2 TRIAL EVALUATING PEMVIDUTIDE, AN INVESTIGATIONAL BALANCED GLUCAGON/GLP-1 DUAL RECEPTOR AGONIST, IN PATIENTS WITH MODERATE TO SEVERE ALCOHOL USE DISORDER (AUD).

ALTIMMUNE ANNOUNCES POSITIVE TOPLINE RESULTS FROM RECLAIM PHASE 2 TRIAL OF PEMVIDUTIDE IN ALCOHOL USE DISORDER

BEST OF EASL ORAL PRESENTATION HIGHLIGHTS MEANINGFUL REDUCTIONS IN TRIGLYCERIDES, CHOLESTEROL, AND BLOOD PRESSURE, ALONG WITH IMPROVEMENTS IN KEY METABOLIC RISK FACTORS

PEMVIDUTIDE DEMONSTRATES SIGNIFICANT METABOLIC IMPROVEMENTS IN PATIENTS WITH MASH IN NEW 48WEEK IMPACT PHASE 2B DATA PRESENTED AT EASL 2026

GAITHERSBURG, MD., MAY 27, 2026 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING PEMVIDUTIDE TO ADDRESS SERIOUS LIVER DISEASES, TODAY ANNOUNCED THAT MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES:

ALTIMMUNE TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

CONCURRENT IMPROVEMENT ACROSS KEY NON-INVASIVE TESTS UNDERSCORES CONVERGENCE OF PEMVIDUTIDE EFFECTS ON MASH DISEASE ACTIVITY AND FIBROSIS AI-BASED DIGITAL PATHOLOGY ANALYSES FURTHER DEMONSTRATE ANTIFIBROTIC EFFECTS OF PEMVIDUTIDE AT 24 WEEKS GAITHERSBURG, MD., MAY 27, 2026 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING PEMVIDUTIDE TO ADDRESS SERIOUS LIVER DISEASES, TODAY ANNOUNCED THAT NEW ANALYSES OF DATA FROM THE IMPACT PHASE 2B TRIAL DEMONSTRATED THAT TREATMENT WITH PEMVIDUTIDE, AN INVESTIGATIONAL, BALANCED 1:1 GLUCAGON/GLP-1 DUAL RECEPTOR AGONIST, IS ASSOCIATED WITH CONCURRENT IMPROVEMENTS ACROSS MULTIPLE NON-INVASIVE TESTS (NITS) OF METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) ACTIVITY AND FIBROSIS.

NEW IMPACT PHASE 2B DATA HIGHLIGHT CONCURRENT IMPROVEMENTS ACROSS MULTIPLE NON-INVASIVE MARKERS AND QFIBROSIS-MEASURED FIBROSIS REGRESSION WITH PEMVIDUTIDE IN MASH AT EASL 2026

INITIATION OF PERFORMA PHASE 3 MASH TRIAL PLANNED FOR SECOND HALF 2026 $535 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS AS OF APRIL 30, 2026 WEBCAST TO BE HELD TODAY AT 8:30 A.M. ET GAITHERSBURG, MD.

ALTIMMUNE ANNOUNCES FIRST QUARTER 2026 FINANCIAL RESULTS AND BUSINESS UPDATE

ABSTRACT PRESENTING 48-WEEK IMPACT PHASE 2B EFFICACY AND SAFETY DATA SELECTED FOR INCLUSION IN BEST OF EASL 2026 BY EASL

ALTIMMUNE TO PRESENT RESULTS OF PEMVIDUTIDE IN MASH IN AN ORAL PRESENTATION AND MULTIPLE POSTER PRESENTATIONS AT EASL CONGRESS 2026

GAITHERSBURG, MD., MAY 06, 2026 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING PEMVIDUTIDE TO ADDRESS SERIOUS LIVER DISEASES, TODAY ANNOUNCED THAT IT WILL REPORT ITS FIRST QUARTER 2026 FINANCIAL RESULTS ON WEDNESDAY, MAY 13, 2026.

ALTIMMUNE TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS AND PROVIDE BUSINESS UPDATE ON MAY 13, 2026

TICKER CHANGE REFLECTS THE COMPANY'S CONTINUED EVOLUTION ACROSS PAYMENTS, TOKENIZATION AND AI-DRIVEN INFRASTRUCTURE LAS VEGAS, NV / ACCESS NEWSWIRE / APRIL 29, 2026 / AI FINANCIAL CORPORATION (NASDAQ:AIFC)(FRA:5AR1) ("AIFI" OR THE "COMPANY"), FORMERLY ALT5 SIGMA CORPORATION (NASDAQ:ALTS), A FINTECH COMPANY PROVIDING BLOCKCHAIN-POWERED PAYMENT, TRADING, AND SETTLEMENT INFRASTRUCTURE FOR DIGITAL ASSETS, TODAY ANNOUNCED THAT ITS COMMON STOCK WILL BEGIN TRADING UNDER ITS NEW CORPORATE NAME AND NASDAQ TICKER SYMBOL, AIFC, EFFECTIVE AT THE OPEN OF MARKET TRADING TODAY, WEDNESDAY, APRIL 29, 2026. THE COMPANY'S COMMON STOCK CEASED TRADING UNDER THE TICKER SYMBOL ALTS FOLLOWING AFTER-MARKET TRADING ON TUESDAY, APRIL 28, 2026, AND NOW TRADES UNDER THE NEW TICKER SYMBOL AIFC.

AI FINANCIAL CORPORATION (FORMERLY ALT5 SIGMA) BEGINS TRADING UNDER NEW NASDAQ TICKER SYMBOL 'AIFC'

$225 MILLION FUNDED AT CLOSING, WITH AN ADDITIONAL $225 MILLION WARRANT TRANCHE FINANCING FUNDS OPERATIONS THROUGH ANTICIPATED PHASE 3 MASH 52-WEEK DATA READOUT FINANCING WAS LED BY DEEP TRACK CAPITAL, WITH PARTICIPATION FROM TCGX, VIKINGGLOBAL INVESTORS, RA CAPITAL MANAGEMENT, AND OTHER NEW AND EXISTING INVESTORS GAITHERSBURG, MD., APRIL 27, 2026 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING PEMVIDUTIDE TO ADDRESS SERIOUS LIVER DISEASES, TODAY ANNOUNCED THE CLOSING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING CONSISTING OF (I) 64,250,000 SHARES OF ITS COMMON STOCK AND 64,250,000 ACCOMPANYING COMMON STOCK WARRANTS TO PURCHASE SHARES OF COMMON STOCK OR PRE-FUNDED WARRANTS IN LIEU THEREOF AND (II) IN LIEU OF COMMON STOCK, TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE AN AGGREGATE OF UP TO 10,750,000 SHARES OF ITS COMMON STOCK AND 10,750,000 ACCOMPANYING COMMON STOCK WARRANTS TO PURCHASE SHARES OF COMMON STOCK OR PRE-FUNDED WARRANTS IN LIEU THEREOF, EACH AT AN EXERCISE PRICE OF $0.001 PER PRE-FUNDED WARRANT.

ALTIMMUNE ANNOUNCES CLOSING OF $225 MILLION OVERSUBSCRIBED PUBLIC OFFERING OF SECURITIES

GAITHERSBURG, MD., APRIL 22, 2026 (GLOBE NEWSWIRE) -- ALTIMMUNE, INC. (NASDAQ: ALT), A LATE CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING PEMVIDUTIDE TO ADDRESS SERIOUS LIVER DISEASES, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING CONSISTING OF (I) 64,250,000 SHARES OF ITS COMMON STOCK AND ACCOMPANYING COMMON STOCK WARRANTS TO PURCHASE AN AGGREGATE OF 64,250,000 SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF) AND (II) IN LIEU OF COMMON STOCK, TO CERTAIN INVESTORS THAT SO CHOOSE, PRE-FUNDED WARRANTS TO PURCHASE AN AGGREGATE OF UP TO 10,750,000 SHARES OF ITS COMMON STOCK AND ACCOMPANYING COMMON STOCK WARRANTS TO PURCHASE AN AGGREGATE OF 10,750,000 SHARES OF COMMON STOCK (OR PRE-FUNDED WARRANTS IN LIEU THEREOF), AT AN EXERCISE PRICE OF $0.001 PER PRE-FUNDED WARRANT. THE COMMON STOCK AND PRE-FUNDED WARRANTS ARE BEING SOLD IN COMBINATION WITH AN ACCOMPANYING COMMON STOCK WARRANT TO PURCHASE ONE SHARE OF COMMON STOCK (OR PRE-FUNDED WARRANT IN LIEU THEREOF) ISSUED FOR EACH SHARE OF COMMON STOCK OR PRE-FUNDED WARRANT SOLD. THE ACCOMPANYING COMMON STOCK WARRANT HAS AN EXERCISE PRICE OF $3.00 PER SHARE, IS IMMEDIATELY EXERCISABLE FROM THE DATE OF ISSUANCE AND WILL EXPIRE UPON THE EARLIER OF (I) THE FIFTH ANNIVERSARY OF THE ORIGINAL ISSUANCE DATE AND (II) FORTY-FIVE DAYS FOLLOWING THE COMPANY'S PUBLIC ANNOUNCEMENT OF A SUCCESSFUL DATA READOUT OF ITS PHASE 3 TRIAL OF PEMVIDUTIDE IN METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH). THE COMBINED OFFERING PRICE OF EACH SHARE OF COMMON STOCK AND ACCOMPANY COMMON STOCK WARRANT IS $3.00. THE COMBINED OFFERING PRICE OF EACH PRE-FUNDED WARRANT AND ACCOMPANYING COMMON STOCK WARRANT IS $2.999. THE OFFERING IS EXPECTED TO CLOSE ON OR ABOUT APRIL 24, 2026, SUBJECT TO SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

Altimmune, Inc.

ALT

Price

Financial Reports

No items found.

Press Releases

Altimmune, Inc.

ALT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

ALT